Blood cancers, Cell type, High grade lymphoma, Lymphoma, Myeloma, Non-Hodgkin lymphoma (NHL)
Open
Phase 1/2
This trial is looking at a new drug called DTP3 for diffuse large B cell lymphoma or myeloma.
It is for people whose treatment has stopped working or their cancer has got worse.
Recruitment start: 1 July 2022
Recruitment end: 31 March 2027
Please note: In order to join a trial you will need to discuss it with your doctor, unless otherwise specified.
Dr Aris Chaidos
Imperial College London
Institute of Cancer Research (ICR)
Medical Research Council (MRC)
Last reviewed: 14 Mar 2025
CRUK internal database number: 18444